Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 833 results for "daiichi sankyo"

FDA to Review New Narcotic Analgesic Combo for Pain
Monthly Prescribing Reference

Charleston Laboratories And Daiichi Sankyo Announce FDA Accept...

/PRNewswire/ --Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CL-108 for the relief of moderate to severe pain while ... BioSpace, 1 week ago

31 images for daiichi sankyo

Business Insider, 3 weeks ago
Reuters India, 3 weeks ago
Channel NewsAsia, 3 weeks ago, 3 weeks ago
Njbiz, 2 weeks ago
Lebanon Daily Star, 3 weeks ago
Money Control, 4 weeks ago
Yahoo! India, 1 month ago
Pharma Letter, 1 month ago
Reuters India, 1 month ago

Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session

Comments Comment on
 AndhraNews.net1 week ago


. DAIICHI SANKYO (NASDAQ:DSNKY) Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very ...
 INO.com4 days ago Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary [Global Data Point]  Pharmacy Choice1 week ago Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer NSCLC  Pharmacy Choice1 week ago DAIICHI SANKYO : Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer NSCLC  4 Traders2 weeks ago
Money Control

Sun Pharma, Daiichi terminate transaction pacts

Daiichi Sankyo, Daiichi Sankyo (Thailand) Ltd, Sun Pharmaceutical Industries Ltd, Ranbaxy (Netherlands) BV and Ranbaxy (Thailand) Company Ltd entered into a termination agreement on May 26, 2016.
 Money Control4 weeks ago

DAIICHI SANKYO : Japan Research Foundation for Clinical Pharmacology 9th Annual Clinical Pharmacology Research Award

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders2 days ago Five researchers win Japan Research Foundation for Clinical Pharmacology Research Award  PharmaBiz1 day ago 2016 Japan Pharma Outlook - growth drivers of 12 major Japanese biopharma companies  Before It's News3 days ago

Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation TOKYO, June 13, 2016 /PRNewswire/ -- Daiichi Sankyo Co., Ltd (JP: 4568.T, OTC Pink:DSNKY) based in Tokyo, and focused on pharmaceutical ...
 Nasdaq1 week ago Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, June 9th, 2016  BioSpace2 weeks ago DAIICHI SANKYO : to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, June 9th, 2016  4 Traders2 weeks ago

Nikkei edges up in choppy trade amid volatility in currency market

* Foreign holdings of Japan stocks fall in latest fiscal year * Drugmaker Daiichi Sankyo soars on share buyback plan By Ayai Tomisawa TOKYO, June 21 (Reuters) - Japan's Nikkei share average edged up on Tuesday morning in choppy trade, but gains ...
 Yahoo! Finance4 days ago Nikkei rise in choppy trade amid volatility  Financial Express Bangladesh4 days ago

BRIEF-Daiichi Sankyo plans 28 mln shares repurchase

June 20 Daiichi Sankyo Co Ltd : * Says it plans to buy 28 million shares (4.1 percent outstanding) back, for up to 500 million yen, from June 21 to Oct. 28 Source text in Chinese: Further company coverage: (Beijing ...
 Reuters UK5 days ago BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock  Reuters UK5 days ago

Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering. Need fast access to comprehensive SPC, data ...
 Benzinga.com3 weeks ago New Market Research Report: Transmembrane Prolyl 4-Hydroxylase - Pipeline Review, H1 2016  Digital Journal1 day ago New Market Report: Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016  Digital Journal1 day ago Global Myelodysplastic Syndrome Pipeline Report 2016 - Pipeline Review of 92 Therapeutic Companies - Research and Markets  4 Traders1 day ago

VideoNektar Therapeutics VP talks to TPL about Daiichi Sankyo deal on Onzeald04-06-2016

CHICAGO: Dr Mary Tagliaferri, vice president of clinical development at Nektar Therapeutics (Nasdaq: NKTR) talks to the Pharma Letter about the company's recently announced deal with Daiichi Sankyo (TYO: 4568) on breast cancer drug Onzeald ...
 Pharma Letter2 weeks ago Nektar Licenses European Onzeald Rights ...  Genetic Engineering News3 weeks ago Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald  Zacks.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo
Get updated on latest news & your favorite topics right in your inbox!
Happening by Location Click on any location on map to view latest news by location
More     Less